Human monoclonal antibodies against
View Patent ↗Isolated human monoclonal antibodies which bind to Anthrax protective antigen are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are derivatives of the human antibodies (e.g., bispecific antibodies and immunoconjugates), pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
1. An isolated monoclonal antibody, or antigen binding portion thereof, that binds to B. anthracis protective antigen comprising a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 8, 12 and 16.
2. An isolated monoclonal antibody, or antigen binding portion thereof, that binds to B. anthracis protective antigen comprising a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 10, 14, and 18.
3. An isolated monoclonal antibody, or antigen binding portion thereof, that binds to B. anthracis protective antigen comprising:
(a) a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 8, 12 and 16; and
(b) a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 10, 14 and 18.
4. An isolated monoclonal antibody, or antigen binding portion thereof, that binds to B. anthracis protective antigen, comprising heavy and light chain amino acid sequences selected from the group consisting of SEQ ID NOs: 2 and 6, SEQ ID NOs: 8 and 10, SEQ ID NOs: 12 and 14, and SEQ ID NOs: 16 and 18, respectively.
5. The monoclonal antibody of claim 4 wherein the antibody is a human antibody.
6. An isolated monoclonal antibody or antigen binding portion thereof, which specifically binds with an affinity of at least 10 7 M −1 to an epitope on B. anthracis protective antigen recognized by the antibody of claim 4 .
7. The antibody of claim 4 , which neutralizes a Bacillus anthracis toxin in a toxin neutralization assay.
8. The antibody of claim 7 , where the toxin neutralization assay employs a cell from a tissue selected from nervous, heart, lung, and bone marrow.
9. The antibody of claim 8 , where the cell is a macrophage.
10. The antibody of claim 4 , comprising a human IgG heavy chain and a human kappa light chain.
11. The antibody of claim 4 , comprising an IgG1 or IgG3 heavy chain.
12. The antibody of claim 4 , wherein the antibody is a Fab fragment or a single chain antibody (scFv).
13. The antibody of claim 4 , wherein the antibody exhibits higher affinity for PA63 over PA 83 according to standard ELISA.
14. A pharmaceutical composition comprising the antibody of claim 4 , and a pharmaceutically acceptable carrier.
15. The isolated antibody of claim 4 , wherein the heavy and light chain variable regions comprise the amino acid sequences shown in SEQ ID NOs: 2 and 6, respectively.
16. The isolated monoclonal antibody of claim 4 , wherein the heavy and light chain variable regions comprise the amino acid sequences shown in SEQ ID NOs: 8 and 10, respectively.
17. The isolated monoclonal antibody of claim 4 , wherein the heavy and light chain variable regions comprise the amino acid sequences shown in SEQ ID NOs: 12 and 14, respectively.
18. The isolated monoclonal antibody of claim 4 , wherein the heavy and light chain variable regions comprise the amino acid sequences shown in SEQ ID NOs: 16 and 18, respectively.
19. An isolated monoclonal antibody, or antigen binding portion thereof, that binds to B. anthracis protective antigen comprising:
a) a heavy chain CDR1 sequence comprising SEQ ID NO:24, a heavy chain CDR2 sequence comprising SEQ ID NO:22, a heavy chain CDR3 sequence comprising SEQ ID NO:20, a light chain CDR1 sequence comprising SEQ ID NO:36, a light chain CDR2 sequence comprising SEQ ID NO:34, and a light chain CDR3 sequence comprising SEQ ID NO:32;
b) a heavy chain CDR1 sequence comprising SEQ ID NO:42, a heavy chain CDR2 sequence comprising SEQ ID NO:40, a heavy chain CDR3 sequence comprising SEQ ID NO:38, a light chain CDR1 sequence comprising SEQ ID NO:48, a light chain CDR2 sequence comprising SEQ ID NO:46, and a light chain CDR3 sequence comprising SEQ ID NO:44;
c) a heavy chain CDR1 sequence comprising SEQ ID NO:54, a heavy chain CDR2 sequence comprising SEQ ID NO:52, a heavy chain CDR3 sequence comprising SEQ ID NO:50, a light chain CDR1 sequence comprising SEQ ID NO:60, a light chain CDR2 sequence comprising SEQ ID NO:58, and a light chain CDR3 sequence comprising SEQ ID NO:56; or
d) a heavy chain CDR1 sequence comprising SEQ ID NO:66, a heavy chain CDR2 sequence comprising SEQ ID NO:64, a heavy chain CDR3 sequence comprising SEQ ID NO:62, a light chain CDR1 sequence comprising SEQ ID NO:72, a light chain CDR2 sequence comprising SEQ ID NO:70; and a light chain CDR3 sequence comprising SEQ ID NO:68.
20. The isolated monoclonal antibody of claim 19 comprising a heavy chain CDR1 sequence comprising SEQ ID NO:24, a heavy chain CDR2 sequence comprising SEQ ID NO:22, a heavy chain CDR3 sequence comprising SEQ ID NO:20, a light chain CDR1 sequence comprising SEQ ID NO:36, a light chain CDR2 sequence comprising SEQ ID NO:34, and a light chain CDR3 sequence comprising SEQ ID NO:32.
21. The isolated monoclonal antibody of claim 19 comprising a heavy chain CDR1 sequence comprising SEQ ID NO:42, a heavy chain CDR2 sequence comprising SEQ ID NO:40, a heavy chain CDR3 sequence comprising SEQ ID NO:38, a light chain CDR1 sequence comprising SEQ ID NO:48, a light chain CDR2 sequence comprising SEQ ID NO:46, and a light chain CDR3 sequence comprising SEQ ID NO:44.
22. The isolated monoclonal antibody of claim 19 comprising a heavy chain CDR1 sequence comprising SEQ ID NO:54, a heavy chain CDR2 sequence comprising SEQ ID NO:52, a heavy chain CDR3 sequence comprising SEQ ID NO:50, a light chain CDR1 sequence comprising SEQ ID NO:60, a light chain CDR2 sequence comprising SEQ ID NO:58, and a light chain CDR3 sequence comprising SEQ ID NO:56.
23. The isolated monoclonal antibody of claim 19 comprising a heavy chain CDR1 sequence comprising SEQ ID NO:66, a heavy chain CDR2 sequence comprising SEQ ID NO:64, a heavy chain CDR3 sequence comprising SEQ ID NO:62, a light chain CDR1 sequence comprising SEQ ID NO:72, a light chain CDR2 sequence comprising SEQ ID NO:70; and a light chain CDR3 sequence comprising SEQ ID NO:68.
24. An isolated monoclonal antibody, or antigen binding portion thereof, that binds to B. anthracis protective antigen and binds to the same epitope as an antibody comprising heavy and light chain variable region sequences comprising amino acid sequences selected from the group consisting of SEQ ID NOs: 2 and 6, SEQ ID NOs: 8 and 10, SEQ ID NOs: 12 and 14, and SEQ ID NOs: 16 and 18, respectively.
25. A method of inhibiting a physiological activity of B. anthracis protective antigen, comprising contacting B. anthracis protective antigen with an effective amount of the antibody of claim 4 , such that the physiological activity of the protective antigen is inhibited.
26. A method of neutralizing a B. anthracis toxin, comprising contacting B. anthracis protective antigen with an effective amount of the antibody of claim 4 , such that the toxin is neutralized.
27. A method of treating anthrax in a host infected with B. anthracis , comprising administering to the host the antibody of claim 4 in an amount effective to treat anthrax.
28. The method of claim 27 , further comprising administering an additional therapeutic agent.
29. The method of claim 28 , wherein the additional therapeutic agent is selected from an antibiotic and vaccine.
30. A method for detecting the presence of B. anthracis protective antigen in a sample comprising:
contacting the sample with the antibody of claim 4 , under conditions which allow for formation of a complex comprising the antibody and the protective antigen; and
detecting the formation of the complex.
31. A method for treating or preventing anthrax in a patient in need of such treatment, comprising the step of administering the antibody of claim 4 in a dosage from 0.1 mg/kg to 100 mg/kg.
32. A method for treating or preventing anthrax in a patient in need of such treatment, comprising the step of administering the antibody of claim 4 in a dosage from 0.3 mg/kg to 50 mg/kg.
33. A method for treating or preventing anthrax in a patient in need of such treatment, comprising the step of administering the antibody of claim 4 in a dosage from 1 mg/kg to 12 mg/kg.
34. The method according to claim 31 , wherein the patient is infected with B. anthracis.
35. The method according to claim 34 , wherein the patient exhibits neutropenia.
36. The method according to claim 34 , wherein the patient exhibits one or more signs and/or symptoms of anthrax.
37. The method according to claim 31 , wherein the patient is not infected with B. anthracis.
38. The method according to claim 31 , wherein the dosage is administered subcutaneously or intravenously.
39. The method according to claim 31 , wherein one or more additional dosages is administered.